Accordingly, several preclinical studies indicated that inhibition of c-Met represents a promising therapeutic strategy paralleled by findings that c-Met overexpression has prognostic value in urogenital cancers, particularly in ovarian cancer. The gene discussed is MET; the disease is ovarian carcinoma.